Tag: clinical trial transparency

KRIs, KPIs and Dashboards to Monitor Plain-Language Summaries & Layperson Results Across Portfolios KRIs, KPIs and Dashboards to Monitor Plain-Language Summaries & Layperson Results Across Portfolios In today’s clinical research landscape, transparency and clear communication with stakeholders are crucial. Key Risk Indicators (KRIs), Key Performance Indicators (KPIs), and dashboards are essential tools used by clinical…

Read More “KRIs, KPIs and Dashboards to Monitor Plain-Language Summaries & Layperson Results Across Portfolios” »

Case Studies: Plain-Language Summaries & Layperson Results That Strengthened Public and Regulator Trust Case Studies: Plain-Language Summaries & Layperson Results That Strengthened Public and Regulator Trust Introduction to Plain-Language Summaries in Clinical Trials Plain-language summaries (PLS) have emerged as a critical component in enhancing transparency and public trust in clinical trials, particularly in the context…

Read More “Case Studies: Plain-Language Summaries & Layperson Results That Strengthened Public and Regulator Trust” »

Digital Tools and Automation to Streamline Plain-Language Summaries & Layperson Results In the ever-evolving landscape of clinical trials, keeping pace with regulatory requirements and enhancing transparency is crucial. One area that is often overlooked yet significantly important is the provision of plain-language summaries (PLS) and layperson results. These documents serve to convey complex clinical trial…

Read More “Digital Tools and Automation to Streamline Plain-Language Summaries & Layperson Results” »

Inspection and Audit Readiness: Documenting Plain-Language Summaries & Layperson Results for Regulators Inspection and Audit Readiness: Documenting Plain-Language Summaries & Layperson Results for Regulators As clinical trials become increasingly complex and subject to scrutiny by regulatory bodies, ensuring transparency through proper documentation has never been more crucial. This guide aims to equip clinical operations, regulatory…

Read More “Inspection and Audit Readiness: Documenting Plain-Language Summaries & Layperson Results for Regulators” »

Aligning Plain-Language Summaries & Layperson Results With ICH, GCP and Transparency Regulations In the evolving landscape of clinical research, ensuring clear communication of trial results is paramount. Regulatory bodies such as the FDA, EMA, and MHRA emphasize the importance of transparency, specifically through the use of plain-language summaries and layperson results. This article aims to…

Read More “Aligning Plain-Language Summaries & Layperson Results With ICH, GCP and Transparency Regulations” »

Plain-Language Summaries & Layperson Results Playbook for High-Profile and Late-Phase Trials Plain-Language Summaries & Layperson Results Playbook for High-Profile and Late-Phase Trials Within the landscape of clinical trials, particularly in late-phase development and high-profile studies, the emphasis on transparency and effective communication has never been more critical. Among the key components of regulatory compliance is…

Read More “Plain-Language Summaries & Layperson Results Playbook for High-Profile and Late-Phase Trials” »

Plain-Language Summaries & Layperson Results in Practice: Step-by-Step Guide for Sponsors and CROs Plain-Language Summaries & Layperson Results in Practice: Step-by-Step Guide for Sponsors and CROs Clinical trials are integral to advancing medical knowledge and improving patient outcomes. As part of an increasing emphasis on transparency in clinical research, the need for plain-language summaries (PLS)…

Read More “Plain-Language Summaries & Layperson Results in Practice: Step-by-Step Guide for Sponsors and CROs” »

Common Pitfalls in Plain-Language Summaries & Layperson Results—and How to Avoid Costly Findings As clinical trials evolve, so does the necessity for transparency in conveying results to a broader audience. Plain-language summaries and layperson results provide crucial insights to stakeholders, including patients and the public, facilitating a better understanding of clinical research outcomes. However, crafting…

Read More “Common Pitfalls in Plain-Language Summaries & Layperson Results—and How to Avoid Costly Findings” »

Plain-Language Summaries & Layperson Results: Compliance Strategy for US, EU and UK Clinical Programs Clinical trials are a critical component in the development of new therapies, particularly in complex therapeutic areas such as oncology. As clinical research continues to evolve, regulations surrounding clinical trial transparency have become increasingly stringent. This article provides a comprehensive, step-by-step…

Read More “Plain-Language Summaries & Layperson Results: Compliance Strategy for US, EU and UK Clinical Programs” »

How to Design Plain-Language Summaries & Layperson Results That Meets FDA, EMA and MHRA Expectations How to Design Plain-Language Summaries & Layperson Results That Meets FDA, EMA and MHRA Expectations In the complex landscape of clinical trials, the importance of clear and accessible communication cannot be overstated. Regulatory authorities such as the FDA, EMA, and…

Read More “How to Design Plain-Language Summaries & Layperson Results That Meets FDA, EMA and MHRA Expectations” »